Articles by Jason T. Lee in JoVE
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer Milica Momcilovic1, Sean T. Bailey2, Jason T. Lee3, Charles Zamilpa3, Anthony Jones3, Gihad Abdelhady1, James Mansfield4, Kevin P. Francis5, David B. Shackelford1 1Division of Orthopaedic Surgery, University of California Los Angeles David Geffen School of Medicine In this protocol, we describe how to utilize [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (18F-FDG PET/CT) imaging to measure the tumor metabolic response to the targeted therapy MLN0128 in a Kras/Lkb1 mutant mouse model of lung cancer and coupled imaging with high resolution ex vivo autoradiography and quantitative histology.
Other articles by Jason T. Lee on PubMed
Microscale Radiosynthesis, Preclinical Imaging and Dosimetry Study of [F]AMBF-TATE: A Potential PET Tracer for Clinical Imaging of Somatostatin Receptors Nuclear Medicine and Biology. Jun, 2018 | Pubmed ID: 29747035 Peptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging. Recent developments have greatly simplified such labeling: in particular, labeling of organotrifluoroborates via isotopic exchange can readily be performed in a single-step under aqueous conditions and without the need for HPLC purification. Though an automated synthesis has not yet been explored, microfluidic approaches have emerged for F-labeling with high speed, minimal reagents, and high molar activity compared to conventional approaches. As a proof-of-concept, we performed microfluidic labeling of an octreotate analog ([F]AMBF-TATE), a promising F-labeled analog that could compete with [Ga]Ga-DOTATATE with the advantage of providing a greater number of patient doses per batch produced.